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ORIGINAL ARTICLES
Eversion carotid endarterectomy (CEA) was
introduced in 1970 by Etheredge.1 This procedure
prevents longitudinal arteriotomy of the internal
carotid artery (ICA) and provides optimal correc-
tion of an elongated ICA. Eversion CEA, although
not as widely used as standard CEA, has obtained
consensus and has been shown to be associated with
low perioperative stroke and restenosis rates.1-12
Whether the surgical technique (eversion or stan-
dard CEA) can influence the outcome and durabili-
ty of CEA, however, remains unclear. The rate of
carotid restenosis after CEA can be interpreted as a
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measure of CEA durability. Different studies report-
ed a 50% restenosis of the operated carotid artery,
which occurs in 1.5% to 36% of cases13-20; sympto-
matic restenosis occurs in 2% to 4% of CEAs.16,20,21
The prospective studies that have compared the out-
comes of eversion and conventional CEA have been
few and small; for this reason, definitive conclusions
have not been drawn.4,5,12
To evaluate the feasibility and durability of ever-
sion CEA, a multicenter randomized trial (the
EVERsion carotid Endarterectomy versus Standard
Trial [EVEREST]) was designed to assess the rela-
tionship between eversion CEA and early and late
carotid occlusion, restenosis, and stroke and death
rates. The current report focuses on the study design
and preliminary results. Long-term results will be
provided in a subsequent report.
PATIENTS AND METHODS 
EVEREST is a multicenter randomized trial that
was conducted in Italy from October 1994 through
March 1997. Surgical candidates with carotid steno-
sis were randomly selected to undergo eversion or
standard CEA.
Study objectives. The primary objective of the
EVEREST trial was to assess the major perioperative
and late complication rates and durability of eversion
CEA. Secondary objectives included determination
of the effects of eversion CEA on minor neurologic
and local complications, evaluation of the influence
of intraoperative quality control methods on early
and late outcomes, definition of the role of risk fac-
tors on early and late outcomes after CEA, and
investigation of symptomatic restenosis.
Study population. The study population
included 1353 patients undergoing surgery for
carotid stenosis. Patients were recruited from the
seven centers that were participating in this trial.
Patient recruitment began on October 3, 1994, and
ended on March 20, 1997. 
Risk factors are defined in Appendix I. All patients
underwent preoperative brain scanning (computed
tomography scanning or magnetic resonance imag-
ing) and cervical duplex scanning. Preoperative
angiography was performed in selected cases accord-
ing to the discretion of the surgeon. Based on the
angiogram, carotid stenosis was defined as mild (0%
to 29%), moderate (30% to 69%), or severe (70% to
99%) according to the North American Symptomatic
Carotid Endarterectomy Trial methods for measure-
ment.22,23 When diagnostic angiography was not per-
formed, the definition of carotid stenosis was based
on duplex scan measurement (Doppler velocity shift
and B-mode imaging) and was expressed as the per-
centage of reduction in the vessel diameter.17,24-31
For definitions of duplex criteria, see Appendix II.
Cerebral monitoring for the detection of clamping
ischemia (local anesthesia, electroencephalography,
transcranial Doppler, stump pressure, somatosensory
evoked potentials, and so on) and criteria for shunting
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Fig. 1. Trial profile at 30-day follow-up. 
*Withdrawn from assigned treatment but in follow-up for the intention-to-treat analysis.
**Two patients with both carotid occlusion and major clinical end points.
were those routinely used at the participating institu-
tions and were not standardized throughout the study. 
The study protocol was approved by the ethical
committee of each institution. Patient consent was
obtained before randomization. 
Patient eligibility. Patients for whom the par-
ticipating surgeon planned surgical treatment for
carotid stenosis were included in EVEREST regard-
less of symptoms (symptomatic or asymptomatic
carotid stenosis), degree of carotid stenosis, plaque
extension, and intraoperative details (need of shunt,
ulcerated plaque, and so on).
Eligibility of patients was based on the “uncer-
tainty principle”: when the vascular surgeons were
uncertain as to which CEA technique (eversion or
standard) would be more suitable (“gray area”), the
patient was randomized. Because each surgeon has
different experiences and prejudices (e.g., ability in
shunt insertion, end point control), there were sub-
stantial differences among surgeons regarding which
patients should be randomized.
CEAs requiring shunt insertion were random-
ized only in centers in which the operating surgeon
did not consider shunting to be a contraindication
for eversion CEA. Previous inclusion in other ran-
domized trials was not a criterion for exclusion from
the EVEREST trial. Patients could be enrolled only
once in the study: when bilateral CEA was necessary,
only one CEA was randomized. Exclusion criteria
included emergency CEAs, repeat operation, com-
bined carotid operation, and poor life expectancy.
Randomization. Randomization was carried out
with a computer-generated list prepared for each site
by the central coordinating center. Patients were allo-
cated to eversion or standard CEA through the use of
sequentially numbered sealed envelopes containing
information on the surgical technique to be applied.
Patients were considered eligible for randomization
only when intraoperative assessment revealed feasibil-
ity for both standard and eversion CEA. 
Operative techniques. There were no restric-
tions with respect to the type of anesthesia (local or
general) and surgical details (heparin dose, use of
patch, choice of patch material, indications for
shunting, heparin reversion); thus, parameters varied
among institutions. 
The eversion CEA technique was described in
detail by Raithel and Kasprzak2 and Berguer.3 The
procedure was performed through an oblique tran-
section of the ICA from the common carotid artery
(CCA), endarterectomy by eversion of the ICA,
endarterectomy of the carotid bifurcation and of the
external carotid artery), and reimplantation of the
ICA on the CCA. 
Conventional CEA was performed through a lon-
gitudinal arteriotomy from the CCA bifurcation to
the ICA. Endarterectomy was carried out after care-
ful identification of the cleavage plane.32 Arteriotomy
could be closed using either a simple suture or an
autologous/prosthetic patch, according to the dis-
cretion of the surgeon. 
Study end points. Primary end points were
early and late postoperative carotid restenosis or
occlusion and major stroke and death. Carotid
restenosis was defined as a reduction of at least 50%
of the operated vessel as detected with postoperative
duplex scan examination. The degree of restenosis
was determined by measuring the peak systolic veloc-
ity, end-diastolic velocity, and degree of spectral
broadening (Appendix II). B-mode imaging also was
recorded. Specific duplex scan criteria for defining
stenosis and the correspondent velocity cut points
were based on previous validation studies.17,24-31
Early (within 2 years after CEA) and late restenoses
were defined according to the time of occurrence.
Carotid occlusion and major stroke and death were
defined as early when they occurred perioperatively
and late when they occurred after 30 days. Stroke was
defined as an acute disturbance of focal neurologic
function with symptoms lasting more than 24 hours
that were presumed to be caused by cerebral ischemia
or hemorrhage.33 Stroke was classified as major (dis-
abling stroke = Rankin ‡ 3) or minor (nondisabling
stroke = Rankin <3).34 Disability was evaluated pre-
operatively, at 1 and 6 months, and at each subse-
quent follow-up according to a modified Rankin
scale (Appendix II).34 To simplify the assessment of
disability, after the second interim analysis (June
1996), the Safety Monitoring Committee introduced
a simple validated questionnaire that was adminis-
tered to patients before and after operation and dur-
ing follow-up (Appendix III).35 The secondary end
points were minor stroke, transient ischemic acci-
dent, myocardial infarction, cranial nerve injuries,
neck hematoma, revisions due to technical defects
revealed by intraoperative quality controls, and vas-
cular territory injured at each neurologic event (e.g.,
hemispheric, retinal, ipsilateral or not ipsilateral to
the operated vessel, vertebrobasilar).
Follow-up study. After randomization, patient
evaluation was scheduled at 1, 6, and 12 months and
then yearly for 4 years. Each follow-up visit consist-
ed of a duplex scan examination and clinical evalua-
tion to assess study end points.
Sample size determination. A study sample
size of 650 CEAs was estimated to be necessary on
the basis of an assumed restenosis rate of 6.9%
among patients treated with standard CEA and of
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2.2% over 3 years in patients treated with eversion
CEA. These values were derived from a prospective
study previously carried out at one of the participat-
ing Institutions.12 The trial was designed to confirm
the 4.7% difference in restenosis rate with a = 0.05
and power = 0.80.
The independent External Safety and Efficacy
Data Monitoring Committee examined the available
efficacy and safety data at three interim points dur-
ing the study period and gave indications regarding
the conduct and continuation of the trial. After the
second interim analysis, the committee recommend-
ed an increase in the sample size to at least 1200
patients to ensure that the trial would maintain the
specified power. 
Statistical analysis. Data were analyzed with
the statistical package SPSS (SPSS Inc., Chicago,
Ill.) and EpiInfo software. Demographics and clini-
cal characteristics of the two study groups were com-
pared and analyzed by c 2 test (Yates’ corrected),
Fisher’s exact test (when appropriate), Student’s t
test, and Mantel-Haenszel test when appropriate.
Corresponding odds ratio (OR) and 95% confidence
interval (95% CI) values were calculated. Stepwise
multivariate logistic regression analysis was used to
identify the independent predictors of primary end
points. Variables were considered statistically signifi-
cant at a level of p < 0.05. 
Two analytical strategies were planned: an inten-
tion-to-treat analysis, in which all randomized
patients were considered at risk regardless of com-
pliance with the study protocol, and an on-treat-
ment analysis based on treatment that patients actu-
ally received. Primary analysis of all study outcomes
was conducted on the basis of the intention to treat.
Study organization. EVEREST is an investiga-
tional trial that was conducted in seven Italian centers
within a national collaborative research setting. The
conduct of the study was supervised by the Steering
Committee, External Safety and Efficacy Monitoring
Committee, and Coordinating Center. The Steering
Committee was responsible for the design, conduct,
and analysis of the study. The Steering Committee
was required to provide consent for dissemination of
the results of the study in the form of published
reports. The External Safety and Efficacy Monitoring
Committee was responsible for patient safety and for-
mal interim analysis of efficacy. The Coordinating
Center was the organ that supervised the study and
provided methodologic and administrative support
to all committees and investigators. 
The study team at each center was composed of
a vascular surgery team and a collaborating neurolo-
gist. Study centers, principal investigator, and study
coordinators and collaborators are listed at the end
of this report.
RESULTS
The EVEREST trial recruitment was discontin-
ued after the third interim analysis by the External
Safety Monitoring Committee. At that time (March
20, 1997), 1410 patients were randomly assigned to
either type of surgical technique. Fifty-seven patients
were excluded from the final analysis: 19 for admin-
istrative errors, 2 for protocol deviations, and 36 for
having been enrolled twice. Thus the final analysis
group comprised 1353 patients. Of these, 678 were
allocated to undergo eversion CEA and 675 were
allocated to undergo standard CEA (419 primary
closure, 256 patch). Withdrawal from the assigned
treatment occurred for 1.6% of the patients; 13
withdrawals occurred in patients assigned to under-
go eversion CEA and in nine patients allocated to
undergo standard CEA (OR, 1.4; p = 0.5). Figure 1
displays the recruitment data for the trial.
The mean patient age was 69.3 ± 7.3 years (range,
38 to 92 years). Demographics and baseline clinical
information of the patient population are reported in
Table I. At this time, mean follow-up was 14.9
months (range, 1 to 38 months). When this prelimi-
nary report was being prepared, the 6 month follow-
up was overdue for only 22 patients (13 eversion CEA
and nine standard CEA), but it is expected that most
of these patients will eventually be found.
Indications for surgical treatment are summa-
rized in Table II. Of the overall 286 preoperative
strokes (ipsilateral, contralateral, and vertebrobasi-
lar), 56 (20%) were disabling (Rankin ‡ 3). Surgical
and anesthesiologic details and surgical findings are
reported in Table III.
No significant differences between the two treat-
ment groups were found with respect to age, risk
factors, surgical indications, and intraoperative find-
ings (Tables I, II, and III). The patch was used in
256 CEAs: in 39, the homologous patch was used,
and in 217, the prosthetic patch was used. Thus ran-
domization resulted in a balanced distribution of
patients relative to overall characteristics, with the
exception of shunting (Table III). Shunt was used
more frequently in the standard group (16% vs 11%;
p = 0.01). The Mantel-Haenszel stratified analysis,
however, showed that this unbalance did not modi-
fy the incidence of perioperative stroke or death
(Mantel-Haenszel OR, 1.20; 95% CI, 0.5 to 3.1; p
= 0.9) or early carotid occlusion (Mantel-Haenszel
OR, 1.3; 95% CI, 0.3 to 5.8; p = 0.9) in the two
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study groups. Clamping times were similar (p =
0.09) in the eversion (31.8 ± 15.9 minutes) and
standard (33.4 ± 17.2 minutes) CEA groups.
However, eversion clamping time appeared to be
shorter compared with patch standard procedures,
and this difference was statistically significant (31.7
± 15.9 vs 34.5 ± 14.4 minutes; p = 0.02). When use
of the patch was compared with primary closure pro-
cedures alone, no significant differences were found
in clamping times (34.5 ± 14.4 vs 32.8 ± 18.5 min-
utes; p = 0.2). Quality control procedures were car-
ried out in 1305 (96%) patients, of which 1004
underwent completion angiography, 299 underwent
angioscopy, and two underwent intraoperative
duplex scan. 
The incidence of perioperative major stroke and
death and occlusion of the operated carotid artery in
the study population is reported in Table IV, which
also includes the incidence of secondary outcome
events. There were a total of eight deaths (0.5%): six
in the eversion CEA and two in the standard CEA
group. In the eversion group, three patients died of
ischemic stroke, one died of hemorrhagic stroke, and
two died of myocardial infarction. In the standard
population, two patients died of cardiopulmonary
arrest. Seven patients experienced early carotid occlu-
sion (Table IV): two died of stroke, three had a
minor stroke, one had a transient ischemic accident,
and one had an asymptomatic occlusion. With uni-
variate analysis, there were no statistically significant
differences for perioperative primary and secondary
outcome events in the two study groups or among
primary closure and patched CEAs in the group allo-
cated to undergo standard CEA. The overall 30-day
event rates were 13.3% in the eversion group and
11.4% in the standard group (p = 0.3).
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Table I. Demographics and risk factors of 1353 patients
Eversion CEA Standard CEA
(n = 678) (n = 675)
No. % No. % p value
Mean age (yrs) 69.3 ± 9.8 68.7 ± 8.9 0.2
Males 483 71 509 75 0.09
Alcohol consumption 55 8 75 11 0.07
Smoking 347 51 369 55 0.2
Hypertension 477 70 462 68 0.4
Diabetes 117 17 134 20 0.2
Hypercholesterolemia 350 52 340 50 0.7
Peripheral vascular disease 209 31 222 33 0.4
Coronary artery disease 187 28 213 32 0.1
Atrial fibrillation 25 4 25 4 0.9
Contralateral carotid occlusion 56 8 76 11 0.07
Operated stenosis ‡ 70% 584 86 583 86 0.9
Contralateral stenosis ‡ 70% 131 19 158 23 0.07
Intracranial vessel stenosis* 10 2 9 2 0.9
Cerebral brain infarction** 254 38 262 39 0.6
Preoperative antiplatelet medication 609 90 612 91 0.7
*Detected only in patients who underwent preoperative arteriography (eversion, 516; standard, 506).
**Detected only in patients who underwent computed tomography (eversion, 671; standard, 668)
Table II. Indications for CEA in 1353 patients
Eversion CEA Standard CEA
(n = 678) (n = 675)
No. % No. % p value
Ipsilateral symptoms 300 44 299 44 0.9
TIA or AFX 205 30 195 29 0.6
Stroke or retinal stroke 95 14 104 15 0.5
Contralateral symptoms 52 8 71 11 0.08
Vertebrobasilar symptoms 37 5 38 6 0.9
Asymptomatic 289 43 269 40 0.3
TIA, Transient ischemic attack; AFX, amaurosis fugax. 
Logistic regression analysis confirmed that ever-
sion CEA is not an independent predictor of major
stroke or death rate (hazard ratio, 0.6; 95% CI, 0.5
to 5.2; p = 0.4) and early carotid occlusion (hazard
ratio, 1.5; 95% CI, 0.3 to 6.8; p = 0.6). 
At a mean follow-up of 14.9 months (range, 1 to
38 months), 16 (2.4%) restenoses occurred in the
eversion CEA group and 28 (4.1%) occurred in the
standard CEA group (OR, 0.56; 95% CI, 0.3 to 1.1;
p = 0.08). As displayed in Figure 2, life table esti-
mates of the cumulative risk of restenosis at 3 years
were 5% in the eversion CEA group and 6.6% in the
standard CEA group (log-rank test, p = 0.1).
The ipsilateral stroke rate, including periopera-
tive strokes, was 2.6% (18) in the eversion group and
1.9% (13) in the standard group (OR, 1.4; 95% CI,
0.6 to 3.1; p = 0.4). The overall mortality rate was
4.4% (30 patients) and 4.3% (29 patients) for the
two groups, respectively (OR, 1.1; 95% CI, 0.6 to
1.8; p = 0.9). 
DISCUSSION
EVEREST is the first multicenter randomized
trial of eversion CEA to be performed in a large pop-
ulation. The only previous randomized study failed
to show substantial benefits for the use of eversion
CEA; however, the study was monocentric and
included a relatively small series of patients.4
EVEREST was designed to determine early and
late consequences of treatment with eversion CEA.
The rationale for this study was derived from the rel-
ative reluctance to perform eversion technique,
despite its encouraging results regarding restenosis
rates.2-12 At a time when endovascular treatment for
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Table III. Surgical details and findings in 1353 patients
Eversion CEA Standard CEA
(n = 678) (n = 675)
No. % No. % p value
Local anestheisa 442 65 434 64 0.7
Carotid stenosis
Mild 5 1 6 1
Moderate 64 9 61 9
Severe 609 90 608 90 0.9
Ulcerated plaque 212 31 217 32 0.7
Plaque extension >2 cm 361 53 343 51 0.4
Shunt 74 11 106 16 0.01
Technical defects* 53 8 59 9 0.6
Intraoperative revisions 29 4 20 3 0.2
*Detected by completion angiography, angioscopy, or duplex scan.
Table IV. Incidence of primary and secondary end points at 30 days in 1353 patients
Eversion CEA Standard CEA
(n = 678) (n = 675)
No. % No. % p value OR 95% CI
Perioperative primary end points
Major stroke death 9 1.3 9 1.3 0.8 1 0.4-2.9
Carotid occlusions 4 0.6 3 0.4 1 1.3 0.2-9.1
Perioperative secondary end points
Transient ischemic attack 9 1.2 7 0.9 0.8 1.3 0.4-4.1
Any stroke 15 2.2 13 1.9 0.8 1.2 0.5-2.7
Ipsilateral stroke 14 2.1 12 1.8 0.8 1.2 0.5-2.8
Cranial nerve injuries 26 3.8 25 3.7 0.9 1 0.6-1.9
Neck hematoma 24 3.5 17 2.5 0.3 1.4 0.7-2.8
Myocardial infarction 3 0.4 3 0.4 1 1 0.1-7.5
Overall 30-day events 90 13.3 77 11.4 0.3 1.2 0.9-1.7
TIA, Transient ischemic attack; AFX, amaurosis fugax. 
carotid stenosis is coming of age, we believe that
every possible surgical approach to the carotid artery
should be carefully investigated to compare out-
comes and thus use the optimal treatment strategy. 
Patients in the two study groups were well bal-
anced for overall characteristics and surgical details,
with the exception of shunting. In this regard, we
found that in two centers, prophylactic shunting was
used sporadically. Yet, this occurred more frequently
when standard CEA was performed because the sur-
geon was less comfortable in inserting a nonmanda-
tory shunt while performing eversion CEA. 
In our study, the differences for each early end
point between eversion and standard CEA in the
intention-to-treat analysis were not statistically sig-
nificant. Perioperative results of EVEREST showed
a low rate of major events for both the eversion and
standard groups. 
It has been hypothesized that eversion CEA may
not be safe because of the chance of leaving behind
a distal intimal flap of the ICA, with possible devas-
tating consequences.7 The potential inability of the
eversion technique to effectively secure the end
point of the endarterectomy in the ICA was not con-
firmed in our study, in which 96% of patients under-
went completion angiography, angioscopy, or
duplex scanning (Table III). The results of this trial
showed that eversion CEA did not require increased
intraoperative revisions compared with standard
CEA. Moreover, the similar rate for early carotid
occlusion and neurologic perioperative events does
not support the hypothesis of a potentially unsafe
distal end of the carotid plaque with use of the ever-
sion technique. 
A recent large systematic review from the
Cochrane database showed that carotid patch angio-
plasty is associated with a promising reduction in ipsi-
lateral stroke and death rates and, to a lesser extent, of
carotid occlusion and restenosis.16 In this regard, it
also has been reported that use of the patch may be
associated with certain perioperative risks: a longer
carotid clamping time, increased risk of arterial rup-
ture due to two suture lines and patch material, and
infection or pseudoaneurysm formation.36 From a
statistical standpoint, our data showed that eversion
clamping times were significantly shorter compared
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Fig. 2. Cumulative percentage of patients free of restenosis at 3 years in the eversion (dotted
line) and standard (solid line) groups.
with patching. However, this absolute difference of 3
minutes could likely have little clinical significance.
Use of prosthetic patch material and its related costs
and complications should be considered in the cost-
effectiveness evaluation of CEA with patch.37
Placement of an indwelling shunt has been per-
ceived as problematic while performing eversion
CEA.7 In the eversion population of EVEREST, a
shunt was placed in 11% of patients. Although this
percentage is significantly lower compared with
patients in the standard population who received a
shunt, it was not so small as to consider the eversion
technique prohibitive for shunt placement. In addi-
tion, there were no significant differences in the peri-
operative rates of stroke or death between the two
groups. Depending on the degree and extension of
carotid stenosis, a shunt can be placed before or after
eversion plaque removal. In addition, a shunt can
function as a fixation point to assist and facilitate the
endarterectomy in some cases of both eversion and
standard techniques.
It has been suggested that a more extensive dis-
section of the carotid bifurcation and the distal ICA,
which is required to perform a complete eversion
CEA, can result in a particularly high rate of injuries
of the vagus nerve, superior laryngeal nerves behind
the carotid bifurcation, and carotid body nerves.6,9,38
Our experience, in accordance with others,5,7 showed
that surgical dissection in eversion CEA neither result-
ed in a particularly high rate of damage to the cranial
nerves nor caused more frequent neck hematomas
compared with standard CEA.
Preliminary data on restenosis rates showed a
favorable trend toward eversion CEA that may be
confirmed when a longer follow-up becomes avail-
able. It is our intention to disseminate the late
results of this trial when they become available.
The preliminary results of EVEREST indicate
that eversion CEA is a safe, rapid, easy-to-perform
procedure with a high percentage of feasibility. No
significant differences were observed between ever-
sion and standard CEA regarding early major,
minor, and local complications. Long-term results
are necessary to confirm the role of eversion CEA in
carotid surgery. 
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APPENDIX I: DEFINITIONS OF RISK FAC-
TORS AND NEUROLOGIC STATUS
Alcohol consumption. Daily consumption of
60 g or more. 
Asymptomatic. Patient with no history of
hemispheric, retinal, or vertebrobasilar symptoms.
Clamping time. The longest period of intraop-
erative carotid occlusion (without shunt).
Coronary artery disease. History of myocar-
dial infarction, angina, or ventricular ectopy; recent
or poorly controlled chronic heart failure; recent
myocardial infarction; or unstable or recent onset of
angina.
Degree of carotid stenosis. Percentage of
carotid stenosis calculated from the angiogram with
the equation 1 – (MRL/DL) · 100, where MRL is
minimal residual lumen and DL is distal lumen.22,23
Diabetes. History of or current fasting blood
sugar level of 120 mg/dl or greater (two or more
abnormal results).
Hypercholesterolemia. History or total choles-
terol level of 220 mg/dl or greater.
Hypertension. Either history of high blood
pressure, current treatment with antihypertensive
drugs, or blood pressure of 165/95 mm Hg or
greater on two separate occasions.
Ipsilateral neurologic symptoms. Symptoms
occurring in the same vascular territory of the ran-
domized carotid artery.
Peripheral vascular disease. Intermittent clau-
dication in one or both lower limbs, ischemic rest
pain, or gangrene in the feet or toes.
Rankin Scale. 0, normal; 1, able to carry out all
usual duties and previous activities; 2, unable to
carry out all previous activities but able to look after
own affairs without assistance; 3, requiring some
help to carry out usual activities and to walk; 4,
requiring some help to carry out usual activities and
unable to walk without assistance; 5, unable to walk
or to attend to our bodily needs without assistance;
6, bedridden, incontinent, and requiring constant
nursing care and attention.
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Retinal infarction. Acute total or partial
monocular loss of vision with symptoms persisting
longer than 24 hours; diagnosis to be confirmed by
an ophthalmologist.
Smoking. Daily use of any kind of tobacco.
Stroke. Acute disturbance of focal neurologic
function with symptoms lasting longer than 24
hours and presumed to be caused by cerebral
ischemia or hemorrhage; stroke was classified as
major (disabling stroke = Rankin ‡ 3) or minor
(nondisabling stroke = Rankin <3).
Transient ischemic attack. Acute disturbance
of focal neurologic or monocular function with
symptoms lasting less than 24 hours and assumed to
be due to arterial embolic or thrombotic vascular
disease.
Vertebrobasilar symptoms. History of loss of
consciousness, faintness, generalized weakness, atax-
ia, or a combination with or without sensory distur-
bance, vertigo, imbalance, dizziness, tinnitus, drop
attacks, confusional episodes, or hearing loss.
APPENDIX II: DUPLEX CRITERIA FOR
MEASUREMENT OF CAROTID STENOSIS
Carotid stenosis detected only by Doppler veloc-
ity shift and B-mode imaging was expressed as a per-
centage of diameter reduction in the vessel.17,24-30
The specific duplex scan criteria for defining a steno-
sis of at least 50% included spectral broadening, peak
systolic velocity (PSV) of >125 cm/sec17,24-27; crite-
ria for defining stenosis approaching 70% included
PSV of >130 cm/sec and an end-diastolic velocity
(EDV) of >100 cm/sec.28. Vessels with an EDIV of
>140 cm/sec were classified in the 80% to 99%
stenotic range.24,26 When contralateral carotid occlu-
sion was present, the PSV increased to >140 cm/sec
to define 50% stenosis.29 These velocity cut-points
were based on previous validation studies.17,24-30
Plaque morphology was defined as echolucent or
echogenic based on Gray-Weale criteria.31
APPENDIX III: QUESTIONNAIRE 
ADMINISTERED TO PATIENTS35
Question 1 (before surgery). In the last 2
weeks, did you require help from another person for
everyday activities (i.e., to walk, climb stairs, eat
meals, dress and undress, get out of a bed, use the
toilet, and so on)?
Question 2 (at 30-day follow-up [recovery
data]). Do you feel that you have made a complete
recovery from a new stroke, cranial nerve damage,
or other complications that are CEA related (i.e.,
neck hematoma, hypertension, cardiac ischemia, and
so on)?
Question 3 (at each follow-up evaluation
[recovery and dependency data]). Do you feel
that you have made a complete recovery from a new
stroke or neurologic event after the last clinical eval-
uation?
STUDY ORGANIZATION
Coordinating center. Vascular Surgery Unit,
Policlinico Monteluce, Perugia: Piergiorgio Cao, MD
(principal investigator), Sandro Caporali, MD,
Gianfranco Carlini, MD, Paola De Rango, MD,
Michelangelo Ferri, MD, Giuseppe Giordano, MD,
Massimo Lenti, MD, Milena Maghini, MD, Leonardo
Nardelli, MD, Basso Parente, MD, Gianbattista
Parlani, MD, Fabio Verzini, MD, Simona Zannetti,
MD (surgeons), and Maria Grazia Celani, MD (neu-
rologist). The number of randomized patients were
368 and the number of CEA patients registered and
not randomized during the same time period were
127 (65 for eversion, 32 for patch, and 30 for prima-
ry closure).
Participating centers, listed according to
number of eligible patients entered. Division of
Vascular Surgery, Ospedale S. Agostino, Modena:
Gioacchino Coppi, MD (center coordinator),
Alessandra Nora, MD (surgeon), and Giovanni
Malferrari, MD (neurologist). The number of ran-
domized patients were 357, and the number of CEA
patients registered and not randomized during the
same time period were 116 (52 for eversion, 43 for
patch, and 21 for primary closure).
Division of Vascular Surgery, Ospedale Regionale,
Aosta: Domenico Palombo, MD (center coordinator),
Flavio Peinetti, MD, Bianca Ines Cifiello, MD, Marco
Udini, MD (surgeons), Giuseppe D’Alessandro, MD,
and Marco Di Giovanni, MD (neurologists). The
number of randomized patients were 263, and the
number of CEA patients registered and not random-
ized during the same time period were 136 (51 for
eversion, 10 for patch, and 75 for primary closure).
Division of Vascular Surgery, IREES, Ospedale S.
Raffaele, Milano: Roberto Chiesa, MD (center coordi-
nator), Renata Castellano, MD, Germano Melissano,
MD (surgeons), Giuseppe Magnani, MD, and Giulio
Truci, MD (neurologists). The number of randomized
patients were 168, and the number of CEA patients
registered and not randomized during the same time
period were 39 (16 for eversion, 17 for patch, and six
for primary closure).
Surgical Unit, Ospedale S. Maria delle Croci,
Ravenna: Vincenzo Stancanelli, MD (center coordi-
nator), Elio Piccinini, MD, Rodolfo Santioni, MD
(surgeons), and Gian Giuseppe Rebucci, MD (neu-
rologist). The number of randomized patients were
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141, and the number of CEA patients registered and
not randomized during the same time period were
106 (34 for eversion, 24 for patch, and 48 for pri-
mary closure).
Division of Vascular Surgery, Università dell’
Aquila: Carlo Spartera, MD (center coordinator),
Gennaro Bafile, MD, Ennio Gizzi, MD, Marco
Ventura, MD, Alessandro Varroni, MD (sur-
geons), and Paolo Aloisi, MD (neurologist). The
number of randomized patients were 36, and the
number of CEA patients registered and not ran-
domized during the same time period were 55
(two for eversion, 28 for patch, and 25 for prima-
ry closure).
Division of Vascular Surgery, Ospedale S. Maria
Nuova, Reggio Emilia: Enrico Vecchiati, MD (cen-
ter coordinator), Nicola Tusini, MD (surgeon), and
Donata Guidetti, MD (neurologist). The number of
randomized patients were 20, and the number of
CEA patients registered and not randomized during
the same time period were none.
Steering Committee: Luigi Moggi, MD (chair-
man, Professor of Surgery, University of Perugia),
Piergiorgio Cao, MD (project director), Giuseppe
Giordano, MD (database coordinator), Paola De
Rango, MD (noninvasive study coordinator),
Beatrice Sensi (secretary), and Maria Grazia Celani,
MD (consulting neurologist).
Safety Monitoring Committee: Giuseppe Nenci,
MD (chairman, Professor of Internal Medicine,
University of Perugia), Teresa Cantisani, MD (neurol-
ogist, Ospedale Silvestrini, Perugia), Albano Del
Favero, MD (Associate Professor of Internal Medicine,
University of Perugia), Stefano Ricci, MD (neurolo-
gist, Policlinico Monteluce, Perugia), Enrico Righetti,
MD (neurologist, Policlinico Monteluce, Perugia),
and Carlo Setacci, MD (Associate Professor of
Vascular Surgery, University of Siena).
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